Trial Profile

A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 May 2024 Results of assessing safety, tolerability, and preliminary efficacy of poziotinib from two different dosing schedules in patients with HER2-positive advanced breast cancer presented at the Breast Cancer Research and Treatment
29 Jul 2021 Status changed from active, no longer recruiting to completed.
04 Dec 2020 According to Spectrum media release, data from this trial would be presented at the upcoming San Antonio Breast Cancer Conference (SABCS) to be held December 8 - 11, 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com